Nexium Direct Purchasers Win Class Cert. In Antitrust MDL

Law360, New York (December 11, 2013, 5:25 PM EST) -- A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.

U.S. District Judge William G. Young noted that the defendants raised many of the same objections in their efforts to avoid certification of a class of end-buyers he approved in mid-November, and said the same analysis applies “with full force and effect” to the direct purchasers’ certification bid.

The direct purchasers claim...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.